Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CYTR $4.41 0.7100 +19.19%
ARRY $7.15 0.8250 +13.05%
VBLT $4.12 0.4100 +11.05%
MEIP $2.13 0.1400 +7.04%
FPRX $22.16 1.4200 +6.85%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

BPTH $1.37 -0.0800 -5.52%
FATE $4.58 -0.2100 -4.38%
NLNK $44.66 -1.9800 -4.25%
KERX $10.48 -0.4200 -3.85%
IDRA $2.80 -0.1100 -3.78%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Next > | Last >>

Self-Reported Health Predicts Survival in Breast Cancer

(Medical Xpress/HealthDay News) Apr 24, 2015 - For older women with breast cancer, low self-rated health (SRH) and limited walking ability predict worse all-cause survival at five and 10 years, according to a study published in the April issue of the Journal of the American Geriatrics Society.
read article  



Brain Tumor Growth Stimulated by Nerve Activity in the Cortex, Study Finds

(Stanford Medicine) Apr 23, 2015 - New research shows that high-grade gliomas, the deadliest human brain tumors, increase their growth by hijacking some of the machinery of neuroplasticity, which normally helps the brain form new synapses.
read article 



How to Identify Drugs That Work Best For Each Patient

(MIT News) Apr 22, 2015 - Implantable device could allow doctors to test cancer drugs in patients before prescribing chemotherapy.
read article 



SEER Cancer Statistics Review (CSR) 1975-2012

(NCI) Apr 23, 2015 - The SEER Cancer Statistics Review (CSR), a report of the most recent cancer incidence, mortality, survival, prevalence, and lifetime risk statistics, is published annually by the Data Analysis and Interpretation Branch of the NCI.
read press release 



AZ Seals Immuno-Oncology Deals as Q1 Sales, Earnings, Slip

(PharmaTimes [UK]) Apr 24, 2015 - AstraZeneca has further singled out immuno-oncology as a central vein of its future business with three separate deals seeking to develop new therapies in the field.
read article 



POMALYST (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits Approved by U.S. FDA

(TheStreet) Apr 23, 2015 - Celgene Corporation today announced it has fulfilled the accelerated approval requirements for POMALYST ® (pomalidomide) based on results from MM-003, an international phase III study of POMALYST plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma patients.
read article 



Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients

(Bristol-Myers) Apr 24, 2015 - Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, be granted approval for use in both first-line and previously treated patients with advanced (unresectable or metastatic) melanoma.
read corporate press release 



American Association for Cancer Research Recognizes 2015 Research Grantees at Annual Meeting

(AACR) Apr 22, 2015 - The American Association for Cancer Research (AACR) honored its new grantee recipients at the AACR Annual Meeting 2015, which was held in here, April 18-22.
read press release 



Congratulations to FDA’s Dr. Richard Pazdur, Recipient of the AACR’s Prestigious Distinguished Public Service Award

(FDA.gov/FDA Voice blog) Apr 21, 2015 - The American Association for Cancer Research (AACR) has awarded its 2015 Distinguished Public Service Award to Dr. Pazdur.
read article 



ONS: Edge and Kidney Cancer Association Announce Awareness and Education Initiative

(PRWeb) Apr 23, 2015 - The two organizations aim to provide nursing and patient resources related to treatment options, overcoming barriers to adherence, and industry innovations.
read press release 



American Academy of Nursing Announces Oncology Recommendations in Choosing Wisely® Campaign

(PRWeb) Apr 23, 2015 - Academy releases five cancer specific treatment approaches identified by ONS that are not always necessary or advisable.
read press release 



TESARO Launches Campaign to Raise Awareness of Chemotherapy-Induced Nausea and Vomiting Among Patients With Cancer

(NASDAQ) Apr 23, 2015 - TESARO, Inc today announced the launch of Ask About CINV, a campaign to raise awareness of chemotherapy-induced nausea and vomiting (CINV) and the importance of fostering an open dialogue about CINV among patients and their health care providers.
read article 



What Adverse Event Reports? FDA Warns Galena For a Lack of Procedures

(Wall Street Journal/Pharmalot blog) Apr 22, 2015 - File this under 'Please consult our handbook for proper procedures.' In May 2013, Galena Biopharma acquired Abstral, an opioid painkiller that comes in a tablet and is prescribed for cancer patients.
read article (paid subscription required) 



GTx and the University of Tennessee Research Foundation Enter Into Exclusive License Agreement to Develop UTRF’s SARD Drug Technology

(Yahoo! Finance) Apr 23, 2015 - GTx, Inc. today announced that it has entered into an exclusive worldwide license agreement with the University of Tennessee Research Foundation (UTRF) to develop its proprietary selective androgen receptor degrader (SARD) technology which potentially can degrade and inhibit all forms of androgen receptor (AR), including those resistant to current therapies, in patients with progressive castration-resistant prostate cancer (CRPC).
read article 



Jounce Gets $56m Infusion to Develop Cancer Immunotherapy Programs

(Boston Globe) Apr 22, 2015 - Two-year-old biotech startup Jounce Therapeutics Inc. was expected to announce Thursday it has received a $56 million cash infusion from a consortium of investors to develop medicines taking different approaches to using the body’s immune system to combat cancers.
read article (free registration required) 



AstraZeneca, Juno Latest to Collaborate on Immuno-Oncology Drugs

(Reuters) Apr 23, 2015 - A unit of AstraZeneca Plc has teamed up with Juno Therapeutics Inc to develop combination treatments that use the body's immune system to kill cancer cells.
read article 



Officials Weigh Options to Hold Down Medicare Costs for Hospice

(Kaiser Health News) Apr 23, 2015 - Medicare officials are considering changes in the hospice benefit to stop the federal government from paying twice for care given to dying patients. But patient advocates and hospice providers fear a new policy could make the often difficult decision to move into hospice care even tougher.
read article 



Major Medicare Oncology Reform Bill Introduced by Congressional Leaders; COA Endorses

(COA) Apr 22, 2015 - COA commends Representatives Cathy McMorris Rodgers (R-WA5) and Steve Israel (D-NY3) for introducing the Cancer Care Payment Reform Act of 2015, which establishes a national oncology medical home (OMH) demonstration project for payment reform under the Medicare program.
read article 



New Study Confirms Quality of Care And Cost Efficiency of Integrated Community Oncology Practices

(Yahoo! Finance) Apr 23, 2015 - The Community Oncology Alliance (COA) released a comprehensive study of the value provided and challenges faced by integrated community oncology practices, the foundation of the nation's cancer care delivery system.
read article 



Novo Launches Saxenda in U.S., Sees More Launches in 2015

(Reuters) Apr 22, 2015 - Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker.
read article 



Meet Pharma’s Newest Movers and Shakers

(Wall Street Journal) Apr 22, 2015 - A few years ago, the drug companies dominating mergers-and-acquisitions headlines were largely household names, from Pfizer Inc. and Merck & Co. to Novartis AG.
read article (paid subscription required) 



CMS Proposes 1.1% Bump in Inpatient Care Payments for 2016

(Medscape Medical News) Apr 22, 2015 - Acute care hospitals that report quality data and that have become meaningful users of electronic health records (EHRs) would get a 1.1% increase in Medicare reimbursements under a proposed rule announced by the Centers for Medicare & Medicaid Services (CMS) for fiscal year (FY) 2016.
read article (free registration required) 



Acetylon Presents Data on Synergistic Activity of Selective HDAC6 Inhibition in Preclinical Models of Multiple Myeloma and Mantle Cell Lymphoma at American Association for Cancer Research Annual Meeting

(Acetylon) Apr 22, 2015 - Acetylon Pharmaceuticals, Inc. today announced that it presented comparative preclinical data for the selective HDAC6 inhibitors, ricolinostat and ACY-241, in combination with the immunomodulatory (IMiD®) class of drugs for the treatment of multiple myeloma (MM) and mantle cell lymphoma (MCL).
read corporate press release 



Removal of Ovaries Associated With Lower Risk of Dying of Breast Cancer in Women With BRCA1 Mutation

(Forbes) Apr 23, 2015 - According to results of a new study, women diagnosed with breast cancer who carry a BRCA1 gene mutation, removal of the ovaries–a procedure known as an oophorectomy— reduced the chance of dying from breast cancer by 62%.
read article 



A Frequent Genomic Alteration is Identified in a Rare Subset of Breast Cancer

(CINJ) Apr 22, 2015 - Research from Rutgers Cancer Institute of New Jersey shows genomic profiling identifies genomic mutations in a gene associated with a rare subset of breast cancer – mutations that cannot otherwise be identified with standard clinical analysis of cells and tissue.
read press release